Stock Events

Stock Events

Aurinia Pharmaceuticals 

$15.29
140
+$0.00+0% 08:03 Today

Statistics

Day High
15.29
Day Low
15.25
52W High
19.25
52W Low
10.34
Volume
51,659
Avg. Volume
-
Mkt Cap
2.03B
P/E Ratio
7.31
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.02
0.08
0.18
0.28
Expected EPS
0.22
Actual EPS
N/A

Financials

101.47%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
283.06MRevenue
287.2MNet Income

Analyst Ratings

16.00Average Price Target
The highest estimate is 16.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AUPH. It's not an investment recommendation.
Apple
29
AAPL
Amazon
26
AMZN
Tesla
25
TSLA
NVIDIA
24
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap99.18B
GlaxoSmithKline develops treatments in areas similar to Aurinia, including autoimmune diseases, making them a direct competitor.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie competes in the immunology space, offering drugs that could be alternatives to Aurinia's products.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a broad portfolio that includes treatments for autoimmune diseases, directly competing with Aurinia's offerings.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb has a strong presence in the immunology and oncology sectors, areas where Aurinia is also aiming to make an impact.
AMGEN
AMGN
Mkt Cap224.63B
Amgen focuses on novel therapeutics in areas including inflammation, which overlaps with Aurinia's focus on autoimmune diseases.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the autoimmune disease market.
Novartis
NVS
Mkt Cap286.78B
Novartis offers a range of treatments for autoimmune diseases, competing with Aurinia's lupus nephritis treatment.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences has a focus on inflammatory and respiratory diseases, making it a competitor in the autoimmune treatment market.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca has a diverse portfolio that includes treatments for lupus, directly competing with Aurinia's lupus nephritis drug.
Roche
RHHBY
Mkt Cap334.28B
Roche, through its Genentech division, develops medications for autoimmune diseases, including lupus, making it a competitor.

About

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Show more...
CEO
Kevin C. Tang
Employees
128
Country
Canada
ISIN
CA05156V1022
WKN
000A1W7D4

Listings

STU
DE
IKAP.STU
MU
DE
IKAP.MU
LSE
GB
0UJF.LSE
F
DE
IKAP.F

0 Comments

Share your thoughts

FAQ

What is Aurinia Pharmaceuticals stock price today?▼
The current price of AUPH is $15.29 USD — it has increased by +0% in the past 24 hours. Watch Aurinia Pharmaceuticals stock price performance more closely on the chart.
What is Aurinia Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Aurinia Pharmaceuticals stocks are traded under the ticker AUPH.
Is Aurinia Pharmaceuticals stock price growing?▼
AUPH stock has fallen by -0.52% compared to the previous week, the month change is a -4.2% fall, over the last year Aurinia Pharmaceuticals has showed a +25.12% increase.
What is Aurinia Pharmaceuticals market cap?▼
Today Aurinia Pharmaceuticals has the market capitalization of 2.03B
When is the next Aurinia Pharmaceuticals earnings date?▼
Aurinia Pharmaceuticals is going to release the next earnings report on October 29, 2026.
What were Aurinia Pharmaceuticals earnings last quarter?▼
AUPH earnings for the last quarter are 0.28 USD per share, whereas the estimation was 0.24 USD resulting in a +16.67% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Aurinia Pharmaceuticals revenue for the last year?▼
Aurinia Pharmaceuticals revenue for the last year amounts to 283.06M USD.
What is Aurinia Pharmaceuticals net income for the last year?▼
AUPH net income for the last year is 287.2M USD.
How many employees does Aurinia Pharmaceuticals have?▼
As of August 18, 2026, the company has 128 employees.
In which sector is Aurinia Pharmaceuticals located?▼
Aurinia Pharmaceuticals operates in the Health & Wellness sector.
When did Aurinia Pharmaceuticals complete a stock split?▼
Aurinia Pharmaceuticals has not had any recent stock splits.
Where is Aurinia Pharmaceuticals headquartered?▼
Aurinia Pharmaceuticals is headquartered in EDMONTON, Canada.